# EDGAR Filing Document

**Accession Number:** 0001855644
**File Stem:** 0001104659-23-035233
**Filing Date:** 2023-3
**Character Count:** 6699
**Document Hash:** 25f42910563a099a59f6f1ca03896a29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-035233.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0001104659-23-035233

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230320

**FILED AS OF DATE**: 20230321

**DATE AS OF CHANGE**: 20230321

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Munshi Amit
- **CENTRAL INDEX KEY:** 0001612551

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40598
- **FILM NUMBER:** 23750953

**MAIL ADDRESS:**
- **STREET 1:** C/O EPIRUS BIOPHARMACEUTICALS, INC.
- **STREET 2:** 699 BOYLSTON STREET, 8TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zura Bio Ltd
- **CENTRAL INDEX KEY:** 0001855644
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** 858-247-0520

**MAIL ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JATT Acquisition Corp
- **DATE OF NAME CHANGE:** 20210407

## Ex-24

**Exhibit 24**

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that I, Amit Munshi, hereby constitute and appoint Kimberly Ann Davis my true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for me and in my name, place and stead, to sign any Form ID (Uniform Application for Access Codes to File on EDGAR), reports on Form 3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership of Securities) and Form 5 (Annual Statement of Beneficial Ownership of Securities) relating to transactions by me in ordinary shares or other securities of Zura Bio Limited and all amendments thereto, and to file the same, with the Securities and Exchange Commission and the appropriate securities exchange, granting unto said attorney-in-fact and agent, or her substitute, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her substitute, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall be effective until such time as I deliver a written revocation thereof to the above-named attorney-in-fact and agent.

---

| | | |
|:---|:---|:---|
| Dated: | 3/21/2023 | /s/ Amit Munshi |
|  |  | Amit Munshi |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Munshi Amit<br><sub>(Last) (First) (Middle)</sub><br>4225 EXECUTIVE SQUARE,<br>SUITE 600<br><sub>(Street)</sub><br>LA JOLLA, CA 92037<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Zura Bio Ltd [ ZURA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-20 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Class A Ordinary Shares | 499993<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Share Option (Right to Buy) | <sup>(2)</sup> | 2033-03-20 | Class A Ordinary Shares | 306373 | $8.16 | D |  |

---

### Footnotes:

(1) The Reporting Person was granted Restricted Stock Units on March 18, 2023, which shall vest in four equal, annual installments, beginning on March 18, 2024, subject to the Reporting Person's continuous employment with the Issuer.

(2) The Reporting Person was granted on March 20, 2023 the option to purchase Issuer Class A Ordinary Shares at an exercise price per ordinary share equal to the fair market value of a Class A Ordinary Share at the date of grant, which will become exercisable if the volume weighted average price of the Issuer's Class A Ordinary Shares over twenty trading days is over $30 per Class A Ordinary Share at any time prior to March 20, 2028, subject to the Reporting Person remaining as Non-Executive Chairman of the Board of Directors of the Issuer.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Kimberly Ann Davis, Attorney-in-Fact  
**Date:** 2023-03-21

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**